Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming

Background. Sipuleucel T, an autologous cell-based vaccine targeting prostatic acid phosphatase (PAP), has demonstrated efficacy for the treatment of advanced prostate cancer. DNA vaccines encoding PAP and live attenuated Listeria vaccines have entered clinical trials for patients with prostate canc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Johnson, Laura E., Brockstedt, Dirk, Leong, Meredith, Lauer, Peter, Theisen, Erin, Sauer, John-Demian, McNeel, Douglas G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136874/
https://ncbi.nlm.nih.gov/pubmed/30221049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1456603
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge